Geoffrey Shouse

41PUBLICATIONS
182CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)HaematologyHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (41)

|Oct 22, 2026
Glofitamab with polatuzumab vedotin in relapsed/refractory central nervous system lymphomas.

|Sep 24, 2026
Risk factors for CRS and ICANS with Bispecific Antibodies for Aggressive Lymphomas.

|Jul 30, 2026
Mosunetuzumab: A bispecific CD20 × CD3 antibody for follicular lymphoma with promising evidence in other B-NHL subtypes.

|Jul 04, 2026
CHIME: a novel HLA eplet model associates with non-relapse mortality in haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide.

|Jun 09, 2026
Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

|May 18, 2026
Cyclin-Dependent Kinase 5 Contributes to Bruton's Tyrosine Kinase Inhibitor Resistance via the IRE1α/XBP1 Axis in Mantle Cell Lymphoma.

Pageof 7

Frequent Collaborators

13 joint publications

Narendranath Epperla

10 joint publications

Reem Karmali

9 joint publications

Thomas Ollila

9 joint publications

Alex F Herrera